For many years, the primary forms of cancer treatment have been chemotherapy, radiation and surgery. An amazing breakthrough known as Chimeric Antigen Receptor T cell therapy (CAR T cell therapy) is now being studied in the treatment of various types of cancer, including acute myeloid leukemia, myelodysplastic syndromes, acute lymphoblastic leukemia, blastic plasmacytoid dendritic cell neoplasm and lymphoma.

CAR T cell therapy, or adoptive cell therapy, is a type of treatment in which a patient’s own T cells are manipulated in a lab by adding an artificial receptor, or a “CAR.” In conjunction with the patient’s own T cells, the CAR enables the final product to produce chemicals in the hopes that the “enhanced” product or cells will bind to the cancer cells and kill them.

Some of these unique therapies have already been approved by the US Food and Drug Administration (FDA) and are the first steps toward further groundbreaking science.

Join this live webinar as our featured speakers review the operational and clinical pathways that are helping to bring these technologies to patients.

Keywords:

Speaker

Emile Youssef, MD, PhD, Executive Medical Director, Oncology, Premier Research

Emile holds a Medical Degree from Cairo University, Egypt, a PhD and board certification in oncology from Osaka City University Medical School, Osaka, Japan.

He brings with him an extensive academia and pharma/CRO experience gained over the last 18 years. He worked not only in clinical development but also in medical affairs, supporting development and life cycle management of different hemato/oncology assets. Emile is also experienced in interacting with health & regulatory authorities and global thought leaders.

Emile has published more than 20 peer-reviewed papers in top-rated clinical cancer journals and is a reviewer for cancer research and clinical cancer journals.

Fun fact about him is that he speaks many different languages including fluent Japanese. He lived in Japan for a number of years, and his wife is Japanese as well.

Emile will support Premier’s growth in Oncology, working closely with our internal strategic & BD teams to establish Premier Research as a growing leader in oncology/hematology field. He will also provide medical monitoring support to assigned clinical trials.

Message Presenter

Who Should Attend?

This webinar will appeal to VPs, Directors, Managers, Department Heads, Scientists and Researchers working within:

Clinical Affairs
Clinical R&D
Clinical Research
Clinical Pharmacology
Clinical Operations
Project Management
Regulatory Affairs
Medical Affairs

What You Will Learn

In this webinar, attendees will explore:

Principles of CAR T cell therapy
FDA-approved CAR T cell therapies
Operational and clinical pathways that bring CAR T cell therapies to patients
Challenges with clinical application

Xtalks Partner

Premier Research

Premier Research, a mid-size clinical research company, is dedicated to helping biotech, specialty pharma, and device innovators transform life-changing ideas and breakthrough science into new medical treatments.

As a global company, Premier specializes in the use of innovative technologies for smart study design and trial management to deliver clean, conclusive data to sponsors.

Whether it’s developing product lifecycle strategies, reducing clinical development cycle times, securing access to patients, navigating global regulations, maximizing the impact of limited rare disease data, or providing expertise in specific therapeutic areas, Premier is committed to helping its customers answer the unmet needs of patients across a broad range of medical conditions.

Visit premier-research.com.